GreatBay Bio Stuns Global Bioprocessing Community at BPI East 2025 with AI-Powered Site-Specific Integration Platform

Recently, the world's largest-scale bioprocessing conferenceBPI East 2025 in Boston, USA, successfully concluded.GBB was invited to attend and give a speech, demonstrating to over 3,000 scientists, executives, and technology leaders from around the globe how AI and site-specific integration technology can empower CMC development and drive revolutionary breakthroughs in frontier molecules such as bispecific antibodies and ADCs. (See attachment at the end of the article)On-site Report Materials from Multiple Major Pharmaceutical Companies）

Mr. Guolong Liang, Co-founder and Chairman of Great Bay Bio, and Dr. Liang Chen, Co-founder and CEO, personally attended the booth, conducted on-site technical explanations and demonstrations, and engaged in extensive and in-depth exchanges with global industry peers regarding the development trends in bioprocessing.GBB's booth quickly became the focal point on site, with numerous professionals engaging in enthusiastic discussions around bioprocess innovation technologies.

Dr. Chen Liang delivered a speech titled "Advantages of AI + Site-specific Integration Cell Line Development (AlfaCell) in CMC Bioprocessing, Bi-specific Antibody and ADC Development".An in-depth analysis of how the AlfaCell platform deeply integrates AI technology with targeted integration technology to efficiently address key challenges faced by complex molecules such as bispecific antibodies and ADCs during CMC development, including issues like expression levels, stability, process controllability, and shortened timelines. The presentation attracted a large number of attendees for exchange and discussion, receiving enthusiastic feedback.

Great Bay Bio's Landing This TimeBPI EastThe 2025 stage fully demonstrates GBB's leading strength in AI-driven bioprocess innovation.In the future, Great Bay Bio will continue to practice the vision of making global bioprocess development simpler and more efficient, deepen the integration exploration of AI and biotechnology, provide more efficient and higher-quality process development solutions for the global biopharmaceutical industry, and help innovative therapies benefit patients as soon as possible.

▲Group photo of GBB team